Mounjaro and Diabetic Retinopathy: What UK Patients Should Know (October 2026)

01 · The core answer

Can you take Mounjaro with diabetic retinopathy?

It depends on your eyes, your diabetes control and your wider health, so the answer has to come from your prescriber working with your eye care team. Your prescriber will take extra care, or may recommend against treatment, if you have diabetic retinopathy, so always share your full medical history and medicine list during consultation. There is no honest blanket yes or no. Anyone offering one without looking at your history is not giving you safe advice.

Mounjaro is the brand name for tirzepatide, a once-weekly injection licensed in the UK for weight management in adults and for type 2 diabetes.¹ If you have type 2 diabetes, treatment and monitoring are coordinated differently, so you should tell your prescriber and your usual diabetes team so care stays joined up.¹ Retinopathy is exactly the kind of detail that team needs to know about.

For eye-specific warnings, read the official Mounjaro SmPC and the patient leaflet yourself, and take any questions to your prescriber.¹³

02 · What to do next

The decisions you are actually facing

• Do I tell my prescriber? Yes. Mention retinopathy, any laser or injection treatment you have had, and the date of your last eye screening.
• Do I speak to my eye team? If you are under a hospital eye service, let them know you are considering or starting a new diabetes or weight medicine. They know the current state of your retinas, which we do not.
• Do I keep my screening? Absolutely. Screening is how changes are caught early, and it matters whichever medicine you take.

If you are weighing up tirzepatide generally, our guides on whether Mounjaro causes retinopathy and GLP-1 medicines and diabetic retinopathy cover closely related questions from different angles.

03 · If you decide to go ahead

If you decide to go ahead

If your prescriber and eye team are comfortable, the next step is a consultation. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Our weight loss clinic page explains the wider service.

Be completely open in the questionnaire about your eyes and your diabetes. A prescriber can only make a safe decision on the information you give them, and a candid answer never counts against you.

04 · Why this question matters

Why diabetic retinopathy and tirzepatide get asked about together

People ask because diabetic retinopathy is a condition of long-standing diabetes, and tirzepatide is a diabetes and weight medicine that changes how the body handles blood sugar and appetite. It is sensible to want to know whether the two interact.

Tirzepatide activates two natural gut-hormone receptors, GIP and GLP-1, which help regulate appetite, slow how quickly the stomach empties and improve the way the body responds to insulin.¹ For someone with type 2 diabetes, that is part of why it is used. For someone with retinopathy, the sensible question is what changes in blood sugar control mean for the eyes, and that is a question for the clinicians who can see your retinal images.

For deeper reading on the topic in other forms, see our pages on tirzepatide and retinopathy and retinopathy and GLP-1 treatment.

05 · Reading the official label

How to check the label and prescribing information

The most reliable way to see what the manufacturer says about eyes is to read three documents: the SmPC, the patient information leaflet and the BNF entry. All three are free to read online.

The Summary of Product Characteristics is the professional document. It sets out indications, dosing, special warnings and precautions, and side effects.¹ The patient information leaflet is the plain-language version and comes in the box.¹³ The BNF gives independent prescribing and safety information for tirzepatide.¹¹

When you read them, look in these places:

• The special warnings and precautions section, which lists conditions where extra care is needed.
• The section on side effects, including any listed eye or vision effects.
• The section on use in people with diabetes, including what to do alongside other diabetes medicines.

Bring anything you find to your prescriber. Plain questions work best: "I have retinopathy; does anything in the label apply to me, and how will you monitor me?" That one question tends to produce a clear, individual answer.

Be wary of third-party summaries of the label. They may be from a different country, with different licensing and different product information. UK advice should come from UK documents.

06 · Tell your teams

Who to tell, and what to say

Tell your prescriber, your GP or diabetes nurse and, if you have one, your hospital eye clinic. Keeping all three informed is the single most useful thing you can do.

For the prescriber at EverydayMeds, include:

• That you have diabetic retinopathy, and what stage you have been told it is, if you know.
• Any treatment your eyes have had, such as laser or injections into the eye.
• Your latest screening date and result, or that you are overdue.
• Every medicine you take, especially other diabetes medicines such as insulin or sulfonylureas, because doses of those may need adjusting to avoid low blood sugar.¹³
• Any recent change in vision, including blurring, floaters or dark patches.

For your diabetes team, mention that you are considering tirzepatide for weight or for blood sugar, so that monitoring is coordinated and nobody is surprised by a change in your readings.

For your eye clinic, mention it at your next appointment or, if you are about to start, sooner. They can tell you whether they want any extra check-ups.

Our aftercare includes ongoing monthly reviews, dose-titration and follow-up assessments by the prescribing team, plus side-effect support. Repeat orders re-check suitability, and nothing ships automatically.

07 · Eye screening

Diabetic eye screening still matters

Routine diabetic eye screening is how retinopathy is found and followed, and it should carry on exactly as your invitations say. Starting or stopping a medicine does not replace it.

Screening takes photographs of the back of the eye, usually after drops that widen the pupils. It is quick and painless, though your vision can be blurry for a few hours afterwards, so many people arrange a lift home. If you have already been diagnosed with retinopathy, you may be seen more often or by a hospital eye service rather than the community screening programme.

If you have missed appointments, ring the screening service or your GP surgery and rebook before you start a new treatment. Having a recent baseline picture gives everyone a clearer view of any change later on.

Screening is a safety net, not a symptom checker. If your vision suddenly changes between appointments, get medical help straight away rather than waiting for the next letter.

08 · Warning signs

Vision changes: when to act

Any new or sudden change in your sight needs medical help straight away, whatever medicines you take. Do not wait for your next scheduled appointment.

Get medical help straight away (an eye casualty department, A&E or NHS 111) for symptoms such as:

• Sudden loss or dimming of vision in either eye.
• A shower of new floaters or flashes of light.
• A dark curtain or shadow across your field of view.
• Rapid blurring that does not clear.

If you are told at an appointment that your eyes have changed, tell your prescriber so the plan for your medicine can be reviewed with the full picture.

It is also worth reporting a suspected side effect. The MHRA Yellow Card scheme collects reports from patients and professionals, and it helps regulators watch the safety of medicines over time.¹⁹ Reporting does not mean you are certain the medicine caused the problem. It means you noticed something and want it recorded.

Do not stop or change a prescribed diabetes medicine on your own because of something you read online. Speak to your prescriber first, because stopping can affect blood sugar control.

09 · Other GLP-1 options

What about Ozempic, Wegovy and other GLP-1 medicines?

The same questions apply to any GLP-1 medicine, and the same people should be told. Semaglutide, sold as Wegovy and Ozempic, is a single-action GLP-1 medicine, whereas tirzepatide acts on both GIP and GLP-1 receptors.¹

If you have retinopathy and are choosing between medicines, ask your prescriber to explain the eye-related wording in each product's own SmPC, and ask which fits your diabetes and weight goals.¹⁸

And if you are a person with type 2 diabetes asking who can prescribe it, see whether a diabetic nurse can prescribe Mounjaro.

Whichever medicine you consider, the practical advice is the same: share your eye history, keep your screening and report changes.

10 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

11 · NHS and private routes

NHS and private routes

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions.⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

If you have type 2 diabetes and retinopathy, your diabetes team may already have a view on whether tirzepatide suits you through the NHS. It is worth asking them before going private, because they hold your full records and can monitor you directly.

If you choose a private route, make sure the pharmacy is on the register. Ours is registered with the GPhC under 9012878, and Mounjaro comes through official LillyDirect supply direct from Eli Lilly's UK distribution. Never buy from anyone offering to supply without a consultation or prescription.